Ultivue is an early stage life sciences tools company that seeks to provide the ultimate view into biology. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that vastly improve our understanding of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and will eventually be valuable for clinical diagnostic use. The company's patented technologies enable single molecule detection and visualization of a multitude of biomolecules, including proteins and nucleic acids, the key drivers of cellular functions and indicators of disease states.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/14/15 | $5,150,000 | Series A |
ARCH Venture Partners Hansjorg Wyss | undisclosed |
| 01/24/18 | $20,000,000 | Series B |
6 Dimensions Capital Applied Ventures ARCH Venture Partners  Sangel Capital Yonghua Capital | undisclosed |
